Critical Path Institute’s (C-Path) Translational Therapeutics Accelerator (TRxA) announced today a new research grant awarded to Daniela C. Zarnescu, Ph.D., Professor of Cellular and Molecular Physiology at Penn State University College of Medicine, in collaboration with Jon Njardarson, Ph.D., Professor at the University of Arizona.

关键路径研究所（C-Path）的转化治疗加速器（TRxA）今天宣布，与宾夕法尼亚州立大学医学院细胞和分子生理学教授DanielaC.Zarnescu博士和亚利桑那大学教授JonNjardarson博士合作，获得了一项新的研究资助。

This $250,000 grant will support their innovative project titled “Novel Small Molecules with Neuroprotective Potential in ALS and Related Neurodegenerative Diseases.”Neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), occur when nerve cells in the brain or peripheral nervous system progressively lose structure and/or function and ultimately die.

这项25万美元的拨款将支持他们的创新项目，名为“在ALS和相关神经退行性疾病中具有神经保护潜力的新型小分子”。当大脑或周围神经系统中的神经细胞逐渐丧失结构和/或功能并最终死亡时，就会发生神经退行性疾病，包括肌萎缩侧索硬化症（ALS）。

Significant challenges remain in research and drug development for rare neurodegenerative diseases and advances are needed to improve the lives of those affected. Dr. Zarnescu aims to identify and develop new small molecules that have the potential to protect nerve cells from degeneration. In response to receiving the grant, she expressed her enthusiasm, “I am honored to receive this grant from TRxA, alongside my collaborator Dr.

罕见神经退行性疾病的研究和药物开发仍面临重大挑战，需要取得进展以改善受影响者的生活。博士。Zarnescu旨在鉴定和开发新的小分子，这些小分子有可能保护神经细胞免受变性。作为对获得资助的回应，她表达了她的热情，“我很荣幸能与我的合作者Dr。

Jon Njardarson. Together, we will explore new avenues in neuroprotective therapies for ALS and related diseases. This funding will accelerate our efforts to discover novel treatments that can impact the lives of patients living with these challenging conditions.”TRxA Executive Director, Maaike Everts, Ph.D., commented on the significance of the grant, “We are thrilled to support Dr.

乔恩·贾达森。我们将共同探索ALS和相关疾病的神经保护疗法的新途径。这笔资金将加速我们发现新疗法的努力，这些疗法可以影响患有这些挑战性疾病的患者的生活。”TRxA执行董事Maaike Everts博士评论了这项资助的重要性，“我们很高兴能支持Dr。

Zarnescu and Dr. Njardason’s pioneering research through TRxA. Their collaborative approach aligns with C-Path’s mission to accelerate the development of therapies for devastating diseases like ALS. This grant underscores our commitment to advance scientific discovery that .

Zarnescu和Njardason博士通过TRxA进行的开创性研究。他们的合作方法与C-Path的使命相一致，即加速开发针对ALS等毁灭性疾病的疗法。这笔拨款强调了我们对推进科学发现的承诺。